1. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
- Author
-
Wenchu Lin, Jian Cao, Jiayun Lui, Beshiri, Michael L., Yuko Fujiwara, Francis, Joshua, Cherniack, Andrew D., Geisen, Christoph, Blair, Lauren P., Zou, Mike R., Xiaohua Shen, Kawamori, Dan, Zongzhi Liu, Grisanzio, Chiara, Watanabe, Hideo, Minamishima, Yoji Andrew, Qing Zhang, Kulkarni, Rohit N., Kulkarni, Sabina Signoretti!, and Scott J. Rodigh
- Subjects
HISTONES ,METHYLATION ,CANCER ,RETINOBLASTOMA ,CARRIER proteins ,LYSINE - Abstract
Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcription- ally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation of Rbp2 decreases tumor formation and prolongs survival in Rb1
+/- mice and Menl-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF